



**ROTH** Capital Partners



## ROTH Capital Partners Completes \$24.5 Million Public Offering for Achillion Pharmaceuticals, Inc. (ACHN)

### Client Information

Achillion Pharmaceuticals, Inc. ("Achillion" or the "Company") is an innovative pharmaceutical company dedicated to bringing new treatments to patients with infectious disease. The Company's focus is currently on developing two clinical candidates for the treatment of chronic hepatitis C infection. First, Achillion is developing ACH-1625, a proprietary NS3 protease inhibitor that recently completed a successful proof-of-concept clinical study. Second, the Company is developing ACH-1095, a candidate from a unique class of compounds called NS4A antagonists which have been demonstrated to be synergistic or additive with other inhibitors under development for HCV infection. Achillion is also developing ACH-702, its candidate for the treatment of serious, resistant bacterial infections. Each of these programs was discovered through the Company's own proprietary internal drug discovery efforts (Source: Press Release, Company Website).

### Transaction Information

On January 22, 2010, Achillion announced a firm commitment underwritten public offering of 10,275,000 shares of its common stock at public offering price of \$2.08 per share. On February 2, 2010 ROTH exercised the over-allotment option of 1,541,250 shares to bring the total transaction value to \$24.5 million. The offering of the shares was made pursuant to a registration statement previously filed with the Securities and Exchange Commission. ROTH Capital Partners acted as sole book-running manager for the offering.

### ROTH Capital Partners

ROTH is a full service investment banking firm dedicated to advising public and private emerging growth companies. Headquartered in Newport Beach, California, ROTH offers a wide array of services to both corporate and institutional clients including: initial public offerings, follow-ons, mergers and acquisitions, SPACs, PIPEs, private placements, investment research and institutional sales and trading.

### For recent news about ROTH and upcoming events please visit

[ROTH Press Room](#)

[ROTH Upcoming Conferences & Events](#)

The material, information and facts discussed in this announcement other than the information regarding ROTH Capital Partners, LLC ("ROTH") and its affiliates, are from sources believed to be reliable, but are in no way guaranteed to be complete or accurate. This announcement should not be used as a complete analysis of any companies, securities or topics discussed herein. Additional information is available upon request. This is not, however, an offer or solicitation of the securities discussed. Any opinions or estimates in this announcement are subject to change without notice. An investment in any security based on this announcement may involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Additionally, such investments may involve a high degree of risk and may not be suitable for all investors. No part of this announcement may be reproduced in any form without the express written permission of ROTH. Copyright 2010.



For more information on how ROTH can help you, please contact:

### Investment Banking

#### John Chambers

Managing Director  
Head of Healthcare  
Investment Banking  
646-358-1901  
[jchambers@roth.com](mailto:jchambers@roth.com)

#### Michael Margolis, R.Ph.

Managing Director  
646-358-1902  
[mmargolis@roth.com](mailto:mmargolis@roth.com)

#### Warren Dunnivant II

Vice President  
646-358-1903  
[wdunnivant@roth.com](mailto:wdunnivant@roth.com)

### Equity Capital Markets

#### Aaron Gurewitz

Head of Equity Capital Markets  
949-720-5703  
[agurewitz@roth.com](mailto:agurewitz@roth.com)

#### Lou Ellis

Sr. Vice President  
949-720-5739  
[lellis@roth.com](mailto:lellis@roth.com)

#### Nazan Akdeniz

Sr. Vice President  
949-720-5740  
[nakdeniz@roth.com](mailto:nakdeniz@roth.com)